Aromatase inhibitors--where are we now?
作者信息
Miller W R
机构信息
University Department of Clinical Oncology, Western General Hospital, Edinburgh, UK.
出版信息
Br J Cancer. 1996 Feb;73(4):415-7. doi: 10.1038/bjc.1996.73.
Abstract
摘要
相似文献
1
Aromatase inhibitors--where are we now?芳香化酶抑制剂——我们现在处于什么阶段？
Br J Cancer. 1996 Feb;73(4):415-7. doi: 10.1038/bjc.1996.73.
2
A better medication for treating breast cancer?
Johns Hopkins Med Lett Health After 50. 2002 May;14(3):3.
3
Aromatase inhibitors and breast cancer.芳香化酶抑制剂与乳腺癌
Cancer Treat Rev. 1997 May;23(3):171-87. doi: 10.1016/s0305-7372(97)90037-2.
4
[Aromatase inhibitors: a review of clinical trials].[芳香化酶抑制剂：临床试验综述]
Bull Cancer. 2000 Dec;87 Spec No:31-39.
5
[Aromatase inhibitors].[芳香化酶抑制剂]
Bull Cancer. 2000 Dec;87 Spec No:5.
6
Aromatase inhibitors for hormonal therapy of early-stage breast cancer.用于早期乳腺癌激素治疗的芳香化酶抑制剂
Curr Opin Investig Drugs. 2004 Jun;5(6):605-10.
7
New endocrine approaches in the treatment of breast cancer.
Biomed Pharmacother. 1998;52(3):122-32. doi: 10.1016/S0753-3322(98)80090-5.
8
[Aromatase inhibitors in the treatment of breast cancer].[芳香化酶抑制剂在乳腺癌治疗中的应用]
Rev Med Suisse Romande. 2000 Jun;120(6):495-500.
9
Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.他莫昔芬与芳香化酶抑制剂：2001年圣安东尼奥传来的消息
Cancer Control. 2001 Nov-Dec;8(6):478-9. doi: 10.1177/107327480100800601.
10
Breast cancer face-off.乳腺癌对峙。
US News World Rep. 2002 Jun 3;132(19):54.
引用本文的文献
1
Elevated incidence of fractures in women with invasive breast cancer.浸润性乳腺癌女性骨折发生率升高。
Osteoporos Int. 2016 Feb;27(2):499-507. doi: 10.1007/s00198-015-3246-3. Epub 2015 Aug 21.
2
Estrogen biosynthesis and action in ovarian cancer.卵巢癌中的雌激素生物合成和作用。
Front Endocrinol (Lausanne). 2014 Nov 12;5:192. doi: 10.3389/fendo.2014.00192. eCollection 2014.
3
Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.化学预防类维生素A N-(4-羟基苯基)-视黄酰胺对MCF-7细胞中芳香化酶活性和表达的抑制作用
Br J Cancer. 2000 Aug;83(3):333-7. doi: 10.1054/bjoc.2000.1269.
本文引用的文献
1
2
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.长期使用盐酸法倔唑治疗晚期乳腺癌患者的效果。
J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):683-5. doi: 10.1016/0960-0760(93)90282-2.
3
Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells.雌激素和雄激素受体介导雄甾-5-烯-3β,17β-二醇对人乳腺癌细胞增殖的刺激和抑制作用。
J Steroid Biochem Mol Biol. 1993 Nov;46(5):597-603. doi: 10.1016/0960-0760(93)90187-2.
4
Recent advances in biochemical markers of bone turnover.骨转换生化标志物的最新进展
Clin Chem. 1994 Nov;40(11 Pt 1):1994-5.
5
Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.口服芳香化酶抑制剂伏洛唑对绝经后晚期乳腺癌患者的临床及内分泌影响。
Cancer Res. 1994 Nov 15;54(22):5875-81.
6
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.法倔唑（CGS 16949A）和来曲唑（CGS 20267）对乳腺癌患者芳香化酶活性抑制的影响。
Breast Cancer Res Treat. 1994;30(1):95-102. doi: 10.1007/BF00682744.
7
8
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.芳香化酶抑制剂盐酸法倔唑对乳腺癌患者内分泌的影响
Eur J Cancer. 1994;30A(10):1453-8. doi: 10.1016/0959-8049(94)00281-9.
9
Aromatase inhibitor development for treatment of breast cancer.用于治疗乳腺癌的芳香化酶抑制剂的研发。
Breast Cancer Res Treat. 1995;33(1):19-26. doi: 10.1007/BF00666067.
10
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.来曲唑（CGS 20267）。一种新型强效乳腺癌口服芳香化酶抑制剂的I期研究。
Cancer. 1995 Apr 15;75(8):2132-8. doi: 10.1002/1097-0142(19950415)75:8<2132::aid-cncr2820750816>3.0.co;2-u.
Zotero 插件